Eric Solary, MD, Gustave Roussy Institute, Paris, France, outlines currently used prognostic factors for myelodysplastic/myeloproliferative neoplasms (MDS/MPN), highlighting the need to include novel markers to better predict patient outcomes, including flow cytometry analysis of peripheral blood (PB) cells and inflammatory cytokine levels in the blood and bone marrow. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
